MX2021004300A - Capsulas blandas con matriz de relleno polimerico solido o similar a un gel. - Google Patents

Capsulas blandas con matriz de relleno polimerico solido o similar a un gel.

Info

Publication number
MX2021004300A
MX2021004300A MX2021004300A MX2021004300A MX2021004300A MX 2021004300 A MX2021004300 A MX 2021004300A MX 2021004300 A MX2021004300 A MX 2021004300A MX 2021004300 A MX2021004300 A MX 2021004300A MX 2021004300 A MX2021004300 A MX 2021004300A
Authority
MX
Mexico
Prior art keywords
solid
softgels
gel
fill matrix
polymeric fill
Prior art date
Application number
MX2021004300A
Other languages
English (en)
Inventor
Perez Javier Zumeta
Alberto Prior
Maria Angela Caballo
Isabel Quijada Garrido
Olga Garcia Ballesteros
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of MX2021004300A publication Critical patent/MX2021004300A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Abstract

Formas de dosificación estables, preferiblemente de formulaciones farmacéuticas, que incluyen una masa polimérica sólida o semisólida que lleva principios activos atrapados y que puede formularse para la administración oral en un molde, preferiblemente en una cápsula blanda.
MX2021004300A 2018-10-16 2019-10-16 Capsulas blandas con matriz de relleno polimerico solido o similar a un gel. MX2021004300A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862746184P 2018-10-16 2018-10-16
US201962915231P 2019-10-15 2019-10-15
PCT/US2019/056481 WO2020081649A1 (en) 2018-10-16 2019-10-16 Softgels with solid or gel-like polymeric fill matrix

Publications (1)

Publication Number Publication Date
MX2021004300A true MX2021004300A (es) 2021-06-04

Family

ID=68468809

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004300A MX2021004300A (es) 2018-10-16 2019-10-16 Capsulas blandas con matriz de relleno polimerico solido o similar a un gel.

Country Status (6)

Country Link
US (1) US20210353574A1 (es)
EP (1) EP3866758A1 (es)
AU (1) AU2019362883A1 (es)
BR (1) BR112021005923A2 (es)
MX (1) MX2021004300A (es)
WO (1) WO2020081649A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR123805A1 (es) * 2020-10-16 2023-01-11 Scherer Technologies Llc R P Cápsulas blandas de liberación modificada
US20240058274A1 (en) * 2021-01-11 2024-02-22 Bayer Healthcare Llc Concentrated liquid gel formulations containing naproxen salts

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004029137A2 (en) * 2002-09-25 2004-04-08 Johns Hopkins University School Of Medicine Cross-linked polymer matrices, and methods of making and using same
US8673333B2 (en) * 2002-09-25 2014-03-18 The Johns Hopkins University Cross-linked polymer matrices, and methods of making and using same
EP1709958A1 (de) 2002-12-05 2006-10-11 Symrise GmbH & Co. KG Nahtlose gefüllte Kapseln
WO2005023181A2 (en) * 2003-08-22 2005-03-17 Vista Scientific Polymeric systems for controlled drug therapy
US20070053868A1 (en) 2005-03-08 2007-03-08 Banner Pharmacaps, Inc. Solvent system for enhancing the solubility of pharmaceutical agents
ITMI20062344A1 (it) 2006-12-06 2008-06-07 Ibsa Inst Biochimique Sa Capsule di gelatina molli comprendenti acido acetilsalicilico
US20080312581A1 (en) * 2007-06-06 2008-12-18 Biovaluation & Analysis, Inc. Peptosomes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo
US20110052679A1 (en) * 2009-08-25 2011-03-03 Pharmaceutics International, Inc. Solid naproxen concentrates and related dosage forms
US8287904B2 (en) 2010-08-19 2012-10-16 Lionel Borkan Stable soft capsule dosage form for acetylsalicylic acid
EP2833880B1 (en) * 2012-04-02 2017-08-23 Pharma Seeds Create, LLC Ibuprofen solid oral dosage composition comprising a methacrylic acid copolymer
WO2017095736A1 (en) 2015-12-01 2017-06-08 R.P. Scherer Technologies, Llc Aspirin soft gelatin capsule as a single active or in combination with other actives

Also Published As

Publication number Publication date
AU2019362883A1 (en) 2021-04-29
WO2020081649A1 (en) 2020-04-23
BR112021005923A2 (pt) 2021-06-29
EP3866758A1 (en) 2021-08-25
US20210353574A1 (en) 2021-11-18

Similar Documents

Publication Publication Date Title
MX2017012878A (es) Composiciones gomosas de multicomponentes con nucleo duro.
CL2017003209A1 (es) Unidad de dosificación orodispersable que contiene un componente estetrol
MX2021004300A (es) Capsulas blandas con matriz de relleno polimerico solido o similar a un gel.
CL2016001411A1 (es) Unidad de dosificación farmacéutica solida de desintegración oral que comprende un componente de estetrol; metodo de preparación; uso para la anticoncepción femenina y en terápia de sustitución hormonal femenina.
JP2015523407A5 (es)
MX2008002512A (es) Composiciones de farmaco que contienen matrices de hipromelosa con liberacion controlada.
CO6640264A2 (es) Combinación de gránulos cargados activos con activos adicionales
CO6771406A2 (es) Una composición combinada
MX2018000546A (es) Composiciones farmaceuticas que contienen celecoxib y tramadol.
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
MX2019004554A (es) Forma de dosis farmaceutica de capsula de gelatina blanda con goma guar modificada.
ITMI20050387A1 (it) Nuove capsule di gelatina molle
MX2017005163A (es) Composiciones de liberación prolongada de onapristona y métodos.
EA201691034A1 (ru) Композиции в твердой форме с замедленным высвобождением для перорального введения
CL2023001639A1 (es) Entrega oral de conjugados antisentido que tienen por blanco a pcsk9
MX2017013633A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas.
MX2018010065A (es) Forma de dosificacion oral que comprende rifaximina en forma beta.
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.
AR107222A1 (es) Premezcla y composición farmacéutica para la administración oral de memantina como suspensión permanente o de preparación previa a la administración al paciente y optativamente por sonda de alimentación enteral y procedimientos correspondientes
MX2018015759A (es) Regimenes de dosificacion de vortioxetina para el rapido inicio del efecto antidepresivo.
AR091234A1 (es) Formulaciones farmaceuticas basadas en genotipos o fenotipos, procedimiento para prepararlas
TR201714149A2 (tr) Ulipristal asetat içeren bir tablet formülasyonu.
UY37413A (es) Formulaciones de liberación inmediata de oprozomib
MX2017013634A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo.
JP2017132756A5 (es)